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OBJECTIVES This substudy tested a prospective hypothesis that European Myocardial Infarct Amiodarone
Trial (EMIAT) patients with depressed heart rate variability (HRV) benefit from amiodarone
treatment.
BACKGROUND The EMIAT randomized 1,486 survivors of acute myocardial infarction (MI) aged #75 years
with left ventricular ejection fraction (LVEF) #40% to amiodarone or placebo. Despite a
reduction of arrhythmic mortality on amiodarone, all-cause mortality was not changed.
METHODS Heart rate variability was assessed from prerandomization 24-h Holter tapes in 1,216 patients
(606 on amiodarone). Two definitions of depressed HRV were used: standard deviation of
normal to normal intervals (SDNN) #50 ms and HRV index #20 units. The survival of
patients with depressed HRV was compared in the placebo and amiodarone arms. A
retrospective analysis investigated the prospective dichotomy limits. All tests were repeated in
five subpopulations: patients with first MI, patients on beta-adrenergic blocking agents,
patients with LVEF #30%, patients with Holter arrhythmia and patients with baseline heart
rate $75 beats/min.
RESULTS Centralized Holter processing produced artificially high SDNN but accurate HRV index
values. Heart rate variability index was #20 U in 363 (29.9%) patients (183 on amiodarone)
with all-cause mortality 22.8% on placebo and 17.5% on amiodarone (23.2% reduction, p 5
0.24) and cardiac arrhythmic mortality 12.8% on placebo and 4.4% on amiodarone (66%
reduction, p 5 0.0054). Among patients with prospectively defined depressed HRV, the
largest reduction of all-cause mortality was in patients with first MI (placebo 17.9%,
amiodarone 10.3%, 42.5% reduction, p 5 0.079) and in patients with heart rate $75
beats/min (placebo 29.0%, amiodarone 19.3%, 33.7% reduction, p 5 0.075). Among patients
with first MI and depressed HRV, amiodarone treatment was an independent predictor of
survival in a multivariate Cox analysis. The retrospective analysis found a larger reduction of
mortality on amiodarone in 313 (25.7%) patients with HRV index #19 U: 23.9% on placebo
and 17.1% on amiodarone (28.4% reduction, p 5 0.15). This was more expressed in patients
with first MI: 49.4% mortality reduction on amiodarone (p 5 0.046), on beta-blockers: 69.0%
reduction (p 5 0.047) and with heart rate $75 beats/min: 37.9% reduction (p 5 0.054).
CONCLUSION Measurement of HRV in a large set of centrally processed Holter recordings is feasible with
robust methods of assessment. Patients with LVEF #40% and depressed HRV benefit from
prophylactic antiarrhythmic treatment with amiodarone. However, this finding needs
confirmation in an independent data set before clinical practice is changed. (J Am Coll
Cardiol 2000;35:1263–75) © 2000 by the American College of Cardiology
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The European Myocardial Infarct Amiodarone Trial
(EMIAT) was a randomized, double-blind placebo con-
trolled clinical trial designed to determine whether amioda-
rone would reduce all-cause mortality, cardiac mortality and
presumed arrhythmic death in patients surviving a recent
myocardial infarction (MI) with a left ventricular ejection
fraction (LVEF) #40% and age #75 years. The European
Myocardial Infarct Amiodarone Trial enrolled 1,486 pa-
tients who were followed for a mean of 21 months. There
was no difference between the two treatment groups with
regard to all-cause mortality and cardiac mortality, but there
was a significant 35% risk reduction in presumed arrhythmic
deaths in patients treated with amiodarone (1). This out-
come prompted several considerations.
The risk in patients with LVEF #40% comprises both
arrhythmic and nonarrhythmic death, and some patients
probably died from heart failure after having an arrhythmic
death prevented by amiodarone. Others, who were similarly
protected from an arrhythmic death, probably were not at
high risk of dying from other causes, such as pump failure.
This concept highlights the importance of developing a
clinically feasible approach to select postinfarction patients
at particularly high risk of predominantly arrhythmic death
who would benefit from amiodarone therapy and in whom
death from fatal arrhythmia would not be merely converted
into death from nonarrhythmic cause.
Depressed heart rate variability (HRV) (2) is a recognized
risk factor in survivors of acute MI (3–5) and, compared
with depressed LVEF, predicts more specifically arrhythmic
than nonarrhythmic mortality (6, 7). The design of
EMIAT, therefore, included a hypothesis that a positive
effect of amiodarone would be noted, particularly in the
subgroup of patients with depressed HRV defined accord-
ing to prospectively set criteria. Because of its association
with arrhythmic events rather than with all-cause mortality,
depressed HRV might identify postinfarction patients who
would benefit from prophylactic antiarrhythmic therapy.
Having this in mind, this substudy of EMIAT evaluated
the prospective hypothesis on the effects of amiodarone in
patients with depressed HRV and investigated whether the
prospectively set criteria were correct and whether the
potential benefit of amiodarone might be improved by
redesigning the definition of the patients at high risk of
arrhythmia. The principle goal of the substudy was to
confirm or reject the hypothesis that all-cause mortality in
patients with depressed HRV is reduced on amiodarone.
METHODS
The study utilized data collected during EMIAT and the
analysis of prerandomization Holter recordings completed
before breaking the code of EMIAT. The complete set of
patients enrolled in the trial was analyzed, and no patient
was excluded for any reasons other than nonavailability of
data. The distinction between amiodarone and placebo arms
of EMIAT was based on an intention-to-treat analysis, and
cases of therapy discontinuation were not censored for this
analysis.
EMIAT. Details of the trial can be found elsewhere (1).
Briefly, patients were eligible for the trial if they were aged
between 18 and 75 years and if LVEF, determined by
multiple-gated nuclear angiography and assessed between
days 5 and 21 after the index infarction, was #40%. The
exclusion criteria of the trial (1) included documented
bradycardia (,50 beats/min), second and third degree
atrioventricular block and contraindications to amiodarone,
such as thyroid dysfunction. Before randomization, a 12-
lead electrocardiogram was made and a three-channel 24-h
Holter recording was obtained. The majority of Holter
recordings were obtained before hospital discharge; all
recordings were obtained within 21 days of the index
infarction.
For each patient enrolled in the trial, the complete
follow-up period within the trial (mean 664 6 107 days)
was considered. Of the 205 trial patients who died, 31 died
from a documented noncardiac cause. The other 174 deaths
were assumed to be cardiac deaths. Of these, 126 were
witnessed and 48 unwitnessed. Sudden death was defined as
that occurring within 1 h of symptoms or in patients with no
symptoms or stable symptoms and with no left ventricular
failure. When unwitnessed, sudden death was defined as
unexpected death in a patient known to be well (no
progressive left ventricular failure) and with no symptoms or
with stable cardiovascular symptoms. Of the 126 witnessed
deaths, 44 were sudden, of which 41 were documented or
considered to be arrhythmic. Of the 82 witnessed nonsud-
den deaths, six were arrhythmic. Of the 48 unwitnessed
deaths, 36 were considered to be sudden and assumed to be
caused by arrhythmia.
Deaths, as recorded in the database of EMIAT, were
taken as the end points for this study. The classification of
the deaths to noncardiac, cardiac nonarrhythmic and cardiac
arrhythmic as decided by the event committee of EMIAT
was not questioned in this study, and the recorded mortality
categories were used.
Holter recordings and HRV assessment. The preran-
domization Holter recordings were centrally analyzed using
Marquette Laser Holter 8000 Systems (Marquette Medical
Systems, Milwaukee, Wisconsin), and an RR interval dat-
Abbreviations and Acronyms
EMIAT 5 European Myocardial Infarct Amiodarone
Trial
HRV 5 heart rate variability
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
SDNN 5 standard deviation of normal to normal
intervals
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afile was produced for each recording listing the duration of
individual RR intervals measured on a discrete scale with
1/128 s (’7.8 ms) steps and the morphological classification
of individual QRS complexes. The RR interval datafiles
were transferred to another center that was responsible for
assessing HRV in all recordings.
The Holter recording was considered suitable for HRV
analysis if it contained $18 h of analyzable data defined as
the sum of all noise-free RR intervals between sinus rhythm
QRS complexes (that is, patients not having at least 18 h of
analyzable sinus rhythm recording were excluded—e.g.,
patients with atrial fibrillation, pacemaker dependent car-
diac rhythm, etc.). From each recording fulfilling this
criterion, two HRV measures were obtained (2): standard
deviation of normal to normal intervals (SDNN) was
computed as the standard deviation of all analyzable sinus
rhythm RR intervals, and HRV index was computed as the
total number of analyzable sinus rhythm RR intervals
divided by their modal frequency.
Because Holter readings performed in a central laboratory
of the whole trial could not achieve the same precision as in
smaller studies that do not have constraints imposed, the
SDNN values were obtained after automatic “filtering” of
the original RR intervals (3,8); otherwise analyzable RR
intervals were excluded if they differed $20% from the
immediately preceding analyzable RR intervals.
The analysis of the Holter recordings and the subsequent
measurement of HRV was performed, and the HRV data
recorded in the database of EMIAT before the code of the
trial was disclosed.
Patient categories. In order to investigate the combined
effect of depressed HRV with some other recognized risk
stratifiers, and to study populations of patients in whom a
positive effect of amiodarone might be expected based on
previous observations in EMIAT substudies and other
amiodarone trials (9–11), the following six patient catego-
ries were considered in this study:
1) All patients 5 all patients suitable for the study (i.e., for
whom the HRV data were available),
2) patients with first MI 5 patients who had no history of
a definite prior MI,
3) patients on beta-adrenergic blocking agents 5 patients
who were treated with beta-blockers at the time of
EMIAT enrollment,
4) patients with reduced LVEF 5 patients with LVEF
#30%. A separate analysis of these patients was envis-
aged in the design of EMIAT,
5) patients with arrhythmia on Holter 5 arrhythmia signs
were taken as either a mean of ventricular premature
beats $10 per hour of the noise free section of the
Holter recording or at least one triplet of ventricular
premature beats within the entire noise free recording. A
separate analysis of these patients was envisaged in the
design of EMIAT,
6) patients with fast, baseline heart rate 5 patients with
heart rate $75 beats/min recorded in the prerandom-
ization short-term ECG recordings.
Patients with reduced LVEF, with signs of arrhythmia on
Holter and with fast baseline heart rate were studied because
these selectors are known to improve predictive value of
HRV; patients with first MI and patients on beta-blockers
were studied because previous substudies of EMIAT (9)
suggested a possible positive effect of amiodarone in these
populations.
Basic comparisons. To investigate the influence of the
other risk factors on HRV measurements, the values of
individual HRV indexes were compared between patients
with and without a history of prior MI, on and off
beta-blocker treatment at enrollment, with LVEF #30%
and LVEF .30%, with and without arrhythmia signs on
Holter and with resting heart rate $75 beats/min and ,75
beats/min. Further, correlation coefficients were evaluated
between individual HRV indexes and the values of LVEF
and resting heart rate.
To ensure that the randomization of EMIAT did not
lead to an artificial bias in the HRV values, individual HRV
indexes were compared between patients of the placebo and
amiodarone arms of each patient category considered in this
study (as described in the previous section).
To investigate whether the preselection procedure of
EMIAT (that is, selection of patients with LVEF #40%
who are at an increased risk of follow-up mortality), as well
as the selection of patients within the considered categories,
influences the power of depressed HRV to predict adverse
outcome, the values of individual HRV indexes were com-
pared between patients who did and did not survive the
follow-up of EMIAT. These comparisons were performed
separately within the placebo and amiodarone arms of all
patient categories considered.
Prospective substudy. The prospective hypothesis of
EMIAT considered two definitions of depressed HRV:
patients were classified as having depressed HRV if having
(a) SDNN #50 ms or (b) HRV index #20 U (both
definitions were envisaged to be used independently of each
other).
For each of the definitions, the all-cause mortality and
the arrhythmic death during follow-up were compared in
the placebo and amiodarone arms of patients with depressed
HRV and in the placebo and amiodarone arms of patients
with preserved HRV. These comparisons were performed
for all the patient categories considered.
Multivariate Cox analysis. To test whether amiodarone is
an independent predictor of survival in patients with low
HRV after adjusting confounding effects of other risk
factors, multivariate Cox analysis was performed using
amiodarone treatment, LVEF .30%, age #60 years, his-
tory of previous MI, baseline heart rate .75 beats/min,
beta-blocker treatment and arrhythmia sign on Holter as
predictors of total mortality during follow-up. The analysis
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was performed for the total population of the trial, patients
with HRV index #20 U and patients with HRV #20 U
belonging to individual subgroups, as described in the
section “Patient Categories.” For the analysis in the catego-
ries, the risk predictor defining the category was omitted
from the analysis.
Retrospective substudy. In the complete population of
patients for whom the HRV data were available, the values
of SDNN and HRV index measures were sorted, and for
each of these HRV indexes, two dichotomy limits alpha and
beta were identified such that approximately 10% of patients
had the HRV values ,alpha and approximately 40% of
patients had the HRV values ,beta. The interval between
alpha and beta was then divided into approximately 100
steps, and, for each value between alpha and beta, patients
were identified with HRV not greater than the given value.
For each subgroup of patients obtained in this way, the
all-cause mortality was compared in the placebo and amio-
darone arms. These comparisons were performed for all the
patient categories considered. Based on the results of these
comparisons, a retrospective readjustment of the prospec-
tively defined dichotomy limits of SDNN and HRV index
values was attempted to achieve the highest mortality
reduction on amiodarone among patients with reduced
HRV.
Statistics. Data of continuous variables are presented as
mean 6 standard deviation. Comparisons of categorical
variables were performed using Fisher exact test, compari-
sons of continuous variables using two-tail two-sample t test
assuming unequal variances of compared samples, and
survival characteristics were compared by log-rank test of
Kaplan-Meier statistics. Excel 5.0 for Windows package
was used for basic computations including the t test; other
statistical tests were performed by the PC version of the
SAS and Statistica packages. Although precise p values are
presented in all cases, p # 0.05 was considered as a
statistical significance.
RESULTS
Of all the patients enrolled into EMIAT, a suitable Holter
recording was available in 1,216. The remaining 270 pa-
tients included those for whom no RR interval data file was
produced for technical reasons (e.g., Holter tape without an
ECG signal, n 5 225) and those for whom the RR interval
data file did not fulfill the criteria for meaningful HRV
assessment (n 5 45). Of the RR interval files that were
suitable for the analysis, 875 (72.0%), 1,061 (87.3%) and
1,179 (97.0%) had at least 23 h, 22 h and 20 h of analyzable
sinus rhythm data, respectively.
Table 1 shows the clinical and follow-up characteristics of
patients with and without eligible Holter recordings. As no
differences between these two groups were noted, it can be
assumed that the patients with eligible Holter recordings are
representative of the complete population of EMIAT.
Table 2 shows all-cause and cardiac arrhythmic mortality in
different categories of patients with eligible Holter recordings.
Heart rate variability assessment. Figure 1 shows scatter
diagrams of correlations between individual HRV measures
in the complete population of the study. In the complete
population, the correlation coefficient between SDNN and
HRV index values was r 5 0.86. Although this correlation
coefficient is highly statistically significant, it is not partic-
ularly strong, and Figure 1 shows that the individual
measures do not replace each other. In ideal data, the scatter
diagram between HRV index and SDNN should be a
straight line (2). Here, however, the average quality of the
RR interval data affects the statistical measures of HRV and,
despite the “filtering” attempts, leads to artificially high
SDNN values in a large number of cases. It should be noted
that no SDNN value appears below the line of SDNN [ms]






Number of patients 1,216 270
On amiodarone 606 (49.8%) 137 (50.7%) 0.84
Women 184 (15.1%) 48 (17.8%) 0.31
Age (yr) 60.2 6 9.5 61.1 6 9.4 0.17
LVEF (%) 30.1 6 7.2 30.5 6 7.4 0.42
First infarction 864 (71.1%) 198 (73.3%) 0.50
Hypertension 383 (31.5%) 96 (35.6%) 0.20
Baseline heart rate (beats/min) 74.3 6 14.3 74.0 6 15.5 0.74
Thrombolytic therapy 701 (57.6%) 151 (55.9%) 0.63
On beta-blockers 541 (44.5%) 117 (43.3%) 0.74
Noncardiac death 28 (2.30%) 3 (1.11%) 0.34
Nonarrhythmic cardiac death 70 (5.76%) 21 (7.78%) 0.21
Arrhythmic cardiac death 70 (5.76%) 13 (4.81%) 0.66
All-cause death 168 (13.82%) 37 (13.70%) 1.00
LVEF 5 left ventricular ejection fraction.
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’2.5 3 HRV index [U] that would represent a perfect
relationship between the two measures.
Basic comparisons. Table 3 shows the comparison of
HRV measures between patients belonging and not belong-
ing to the individual categories considered in this study. The
correlation coefficients between LVEF and SDNN and
HRV index were r 5 0.19 and 0.22, respectively. The
correlation coefficients between short-term baseline heart
rate and these HRV measures were r 5 20.39 and 20.42,
respectively. Thus, higher HRV values were obtained in
patients with slower heart rate (and consequently in patients
on beta-blockers) and in patients with higher LVEF.
History of previous MI did not influence the HRV values.
Note that SDNN tends to be higher in patients with
arrhythmia signs on Holter while the HRV index values do
not differ between patients with and without arrhythmia
sign. This is almost certainly because on average, the
standard quality of Holter analysis is poorer in patients with
arrhythmia, and this artificially increases the statistical
measures. As seen in Table 3, HRV values were strongly
associated with baseline heart rate dichotomized at 75
beats/min, probably because, in the patients with reduced
LVEF, sympathetic overdrive is frequently the cause of both
reduced HRV and increased heart rate.
While in all other categories, the randomization did not
introduce any bias in terms of HRV values, a trend towards
a possible bias was seen in patients with increased heart rate
among whom patients randomized to amiodarone tend to
have lower HRV values.
Table 4 shows the comparison of HRV values between
survivors and nonsurvivors in individual patient categories.
Generally, depressed global 24-h HRV was statistically
associated with mortality during follow-up in both placebo
and amiodarone arms of individual patient categories. This
association was weakest among patients who were on
beta-blockers at the time of EMIAT randomization, prob-
ably because these patients represent a low risk group among
other patients of the trial (the treatment with beta-blockers
was not randomized in the trial and was based on clinical
judgement). There were important practical differences
between the individual methods for HRV assessment.
Prospective substudy. Table 5 shows the number of pa-
tients in individual patient categories who fulfilled the
prospectively set criteria of depressed HRV. Because of the
influence of RR interval data quality, the criterion SDNN
#50 ms was too tight and selected very few patients, indeed.
On the contrary, the criterion HRV index #20 U performed
as envisaged in the design of the prospective substudy and,
in most patient categories, selected approximately 30% of
patients. Only in patients with LVEF #30% and in patients
with baseline heart rate $75 beats/min were approximately
40% patients selected.
Table 6 shows the comparison of all-cause mortality in
placebo and amiodarone arms of prospectively selected
patients with depressed HRV in individual patient catego-
ries. Although the differences did not reach statistical
significance, the placebo arm mortality of patients with
HRV index #20 U was substantially higher than the
amiodarone arm mortality in all patient categories. Corre-
sponding curves of arrhythmia-free survival are shown in
Figure 2. Table 6 also shows the comparisons of all-cause
Figure 1. Scatter diagram of heart rate variability values obtained
from the RR interval datafiles used in the study.
Table 2. Mortality Levels in Patients With Eligible Holter Recordings (Population of the Substudy)
All-cause Mortality Arrhythmic Mortality
PA AA p Value PA AA p Value
All patients 13.4% 14.2% 0.74 6.7% 4.8% 0.16
Patients with first MI 10.6% 8.5% 0.26 5.8% 2.9% 0.040
Patients on beta-blockers 10.3% 7.8% 0.28 5.2% 2.6% 0.12
Patients with LVEF #30% 18.7% 18.8% 0.91 9.5% 5.6% 0.094
Patients with arrhythmia 19.7% 20.7% 0.82 9.2% 6.6% 0.31
Patients with HR $75 beats/min 19.7% 18.3% 0.64 10.4% 5.2% 0.022
The p values refer to the log-rank test of Kaplan-Meier survival models.
AA 5 amiodarone arm; HR 5 baseline heart rate; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PA 5 placebo arm.
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mortality in placebo and amiodarone arms of prospectively
selected patients with preserved HRV. It should be noted
that the potential benefit of amiodarone, which was previ-
ously noted in patients with first MI and in patients on
beta-blockers (9), was almost exclusively manifested in
patients with reduced HRV because the mortality levels on
Table 3. Heart Rate Variability Measures in Patient Categories Considered in the Study
Patients With First MI
(n 5 864)
Patients With an MI History
(n 5 352)
p Value
SDNN (ms) 94.1 6 35.1 96.2 6 36.6 0.36





SDNN (ms) 97.1 6 36.0 92.8 6 35.1 0.038
HRV index (U) 27.6 6 10.6 25.7 6 10.1 0.0015
Patients With LVEF #30%
(n 5 571)
Patients With LVEF .30%
(n 5 645)
SDNN (ms) 88.7 6 36.4 100.1 6 33.9 2.4 3 1028
HRV index (U) 24.3 6 10.0 28.5 6 10.3 1.1 3 10212
Patients With Arrhythmia
on Holter (n 5 481)
Patients Without Arrhythmia
on Holter (n 5 735)
SDNN (ms) 97.0 6 37.6 93.3 6 34.1 0.083
HRV index (U) 27.1 6 10.4 26.8 6 10.9 0.40
Patients With Baseline
Heart rate $75 beats/min
(n 5 579)
Patients With Baseline Heart
rate ,75 beats/min
(n 5 637)
SDNN (ms) 82.5 6 33.2 105.8 6 33.9 8.1 3 10232
HRV index (U) 22.7 6 9.4 30.0 6 9.9 1.9 3 10237
HRV 5 heart rate variability; MI 5 myocardial infarction; SDNN 5 standard deviation of normal to normal intervals.
Table 4. Heart Rate Variability in Survivors and Nonsurvivors (All-cause Mortality During Follow-up of EMIAT)
Placebo Arm Amiodarone Arm
Deceased Survivors p Value Deceased Survivors p Value
All Patients
Number of patients 82 528 86 520
SDNN (ms) 83.1 6 32.5 97.0 6 34.3 5.2 3 1024 86.9 6 39.7 95.6 6 36.1 0.059
HRV index (U) 22.8 6 9.8 27.2 6 10.3 2.8 3 1024 23.1 6 9.0 27.0 6 10.5 5.0 3 1024
Patients With First Myocardial Infarction
Number of patients 48 403 35 378
SDNN (ms) 85.2 6 34.5 97.0 6 35.4 0.030 78.2 6 25.6 93.7 6 35.1 0.0019
HRV index (U) 23.3 6 10.1 27.2 6 10.6 0.014 21.8 6 7.2 26.6 6 10.5 8.1 3 1024
Patients on Beta-blockers
Number of patients 28 243 21 249
SDNN (ms) 85.7 6 40.8 97.7 6 35.7 0.14 90.1 6 24.9 98.4 6 36.6 0.17
HRV index (U) 23.8 6 10.7 27.7 6 10.7 0.079 24.6 6 7.3 28.1 6 10.6 0.055
Patients With LVEF #30%
Number of patients 53 230 54 234
SDNN (ms) 79.8 6 33.2 91.3 6 33.8 0.026 85.5 6 43.3 88.9 6 37.7 0.60
HRV index (U) 22.0 6 10.2 25.0 6 9.3 0.058 21.7 6 8.7 24.8 6 10.7 0.027
Patients With Arrhythmia on Holter
Number of patients 47 192 50 192
SDNN (ms) 87.1 6 34.9 101.3 6 35.3 0.015 90.6 6 44.7 96.8 6 38.2 0.37
HRV index (U) 23.9 6 10.3 28.1 6 10.7 0.016 23.9 6 9.4 27.0 6 11.2 0.052
Patients With Baseline Heart Rate $75 beats/min
Number of patients 57 232 53 237
SDNN (ms) 76.7 6 30.5 87.8 6 34.4 0.019 74.0 6 31.4 80.7 6 32.4 0.17
HRV index (U) 20.5 6 9.3 23.9 6 9.3 0.017 19.8 6 7.4 22.6 6 9.7 0.020
HRV 5 heart rate variability; SDNN 5 standard deviation of normal to normal intervals.
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placebo and on amiodarone are practically identical in the
subgroup of these patients with preserved HRV.
The reduction of the cardiac arrhythmic mortality on
amiodarone was very dramatic in patients with HRV index
#20 U. Although the cardiac nonarrhythmic mortality
increased on amiodarone, the increase was lower than the
reduction of arrhythmic mortality (only in patients on
beta-blockers were both the cardiac arrhythmic and cardiac
nonarrhythmic mortalities decreased).
Multivariate Cox analysis. Statistical significances of pre-
dictor association with all-cause mortality in individual Cox
analyses performed are shown in Table 7. Compared with
the total population, a trend is very obvious for amiodarone
being an independent predictor of survival in patients with
reduced HRV (HRV index #20 U). Statistical significance
for amiodarone treatment being an independent predictor of
survival has been reached among patients without a history
of previous MI and with reduced HRV.
Retrospective substudy. Of the complete population of
the study, 138 (11.3%) and 463 (38.1%) patients had
SDNN measurements #55 ms and #80 ms, respectively,
and 136 (11.2%) and 471 (38.7%) patients had HRV
indexes #15 U and #22 U, respectively. Consequently, the
ranges of SDNN dichotomy limits from 55 to 80 ms and of
HRV index dichotomy limits from 15 to 22 U were used in
the retrospective study.
Figure 3 shows the dependence of mortality in placebo
and amiodarone arms on the dichotomy limit used to define
depressed HRV. In the total population stratified according
to the values of the HRV index, both the cardiac arrhythmic
and nonarrhythmic mortality increased in the placebo arm
when selecting patients with more and more depressed
HRV. On the contrary, only the cardiac nonarrhythmic
mortality increased in the amiodarone arm while the ar-
rhythmic mortality was not only substantially lower than in
the placebo arm, but also independent of the depressed
HRV. Similar trends were seen in other patient categories,
and the difference between placebo and amiodarone arms
was most pronounced in patients on beta-blockers at the
time of EMIAT randomization.
The reduction of all-cause mortality on amiodarone as a
Table 5. Numbers of Patients Fulfilling the Prospective Criteria of Depressed Heart Rate Variability
HRV Index <20 U SDNN <50 ms
Placebo Amiodarone Placebo Amiodarone
All patients 180 (29.5%) 183 (30.2%) 34 (5.6%) 45 (7.4%)
Patients with first MI 134 (29.7%) 136 (32.9%) 26 (5.8%) 31 (7.5%)
Patients on beta-blockers 74 (27.3%) 73 (27.0%) 11 (4.1%) 10 (3.7%)
Patients with LVEF #30% 109 (38.5%) 114 (39.6%) 24 (8.5%) 33 (11.5%)
Patients with arrhythmia 68 (28.5%) 74 (30.6%) 14 (5.9%) 19 (7.9%)
Patients with HR $75 beats/min 124 (42.9%) 135 (46.6%) 28 (9.7%) 45 (15.5%)
HR 5 baseline heart rate; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
Table 6. All-cause Mortality in Prospectively Selected Patients With Reduced and Preserved Heart Rate Variability
HRV Index < 20 U SDNN < 50 ms
PA AA p Value PA AA p Value
All patients 22.8% 17.5% 0.24 32.4% 26.7% 0.55
Patients with first MI 17.9% 10.3% 0.079 26.9% 19.4% 0.48
Patients on beta-blockers 14.9% 8.2% 0.21 54.5% 10.0% 0.024
Patients with LVEF #30% 27.5% 21.1% 0.33 33.3% 30.3% 0.80
Patients with arrhythmia 33.8% 23.0% 0.19 35.7% 36.8% 0.98
Patients with HR $75 beats/min 29.0% 19.3% 0.075 32.1% 26.7% 0.62
HRV Index > 20 U SDNN > 50 ms
PA AA p Value PA AA p Value
All patients 9.5% 12.8% 0.15 12.3% 13.1% 0.69
Patients with first MI 7.6% 7.6% 0.96 9.6% 7.6% 0.28
Patients on beta-blockers 8.6% 7.6% 0.65 8.5% 7.8% 0.72
Patients with LVEF #30% 13.2% 17.2% 0.29 17.4% 17.3% 0.95
Patients with arrhythmia 14.0% 19.6% 0.20 18.7% 19.3% 0.90
Patients with HR $75 beats/min 11.9% 17.9% 0.17 18.4% 16.9% 0.68
The p values refer to the log-rank test of Kaplan-Meier survival models (to be compared with the p values in the first half of Table 2).
AA 5 amiodarone arm; HR 5 baseline heart rate; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PA 5 placebo arm.
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function of HRV dichotomy is shown in Figure 4, which
also shows the results of statistical comparisons of the
survival in groups with differently depressed HRV. When
selecting more and more patients with depressed HRV (that
is, when loosening the criterion defining depressed HRV),
the statistical comparisons become more and more power-
ful. In this, an “optimum” dichotomy limit of HRV index
#19 U was identified (see Fig. 4). Table 8 and Figure 5
show that when using this dichotomy limit, the mortality
reduction on amiodarone becomes significant in patients
with first MI and in patients on beta-blockers (the dichot-
omy selects approximately 25% of these patients) and almost
reaches statistical significance in patients with increased
baseline heart rate (selecting approximately 40% of these
patients). Table 8 also shows that the mortality levels on
placebo and amiodarone are much less different in patients
with HRV index .19 units and that, similar to the
observation made with the prospective substudy, the poten-
Figure 2. Curves of arrhythmia-free survival in patients selected by a prospectively defined criterion heart rate variability index #20 U.
In each case, the p value corresponds to the log-rank statistics of the Kaplan-Meier survival model. Bold line 5 placebo arm; fine line 5
amiodarone arm. Arrhythmia 5 arrhythmia signs on Holter (see the text for details); fast heart rate 5 baseline short-term heart rate $
75 beats/min; low LVEF 5 left ventricular ejection fraction # 30%; MI 5 myocardial infarction.














Amiodarone treatment 0.9068 0.3221 0.3785 0.0417 0.2404 0.1458 0.4909
Age $ 60 yr 0.0047 0.7253 0.8727 0.8751 0.4955 0.2316 0.2684
LVEF # 30% 0.0072 0.0934 0.6387 0.02631 0.1183 0.2051
MI history 0.0000 0.0000 0.0000 0.0004 0.0091 0.0002
HR $ 75 beats/min 0.0011 0.0056 0.0020 0.0227 0.0233 0.0241
Arrhythmia on Holter 0.0014 0.0229 0.3744 0.0231 0.0204 0.3985
Beta-blocker treatment 0.1442 0.3311 0.9321 0.0867 0.7340 0.5873
HRV index # 20 units 0.0039
The columns of the table show statistical significances obtained in individual multivariate Cox models. The to row identifies the populations used in individual models.
Arrhythmia 5 arrhythmia signs on Holter; BB 5 beta-blocker treatment; First MI 5 patients without a history of previous MI; 1 HR 5 baseline heart rate $ 75 beats
per min; 2 HRV 5 HRV index # 20 U; 2 LVEF 5 LVEF # 30%.
1270 Malik et al. JACC Vol. 35, No. 5, 2000
HRV Substudy of EMIAT April 2000:1263–75
tially positive effect of amiodarone in patients with first MI
and in patients on beta-blockers is solely due to the
mortality reduction among patients with HRV index
#19 U.
A retrospective attempt to optimize the dichotomy of the
SDNN measure does not yield any generally useful selection
criterion. Up to the limit of SDNN #70 ms, the difference
between placebo and amiodarone survival is statistically
significant, while the difference in other patient categories
remains well below statistical significance (Fig. 4). The
criterion SDNN #70 ms selects approximately 24% of
patients on beta-blockers. Again, this lack of any retrospec-
tive improvement of the SDNN dichotomy limit almost
certainly reflects the quality of data that were used to
compute the SDNN values.
DISCUSSION
Being the first prospectively set-up investigation of the
relationship between depressed HRV and prophylactic
treatment in a large population of survivors of acute MI, this
study has implications for the assessment of HRV in large
clinical populations, for its predictive value as well as for the
identification of patients who might benefit from prophy-
lactic antiarrhythmic treatment.
Implications of the study. The analysis of the placebo arm
of the population of EMIAT showed that the predictive
power of depressed HRV is preserved when patients with
depressed LVEF are considered. The HRV values were
significantly lower in nonsurvivors compared with survivors.
The total follow-up mortality of 13.4% in the placebo arm
of this substudy increased to 20.0%, 23.8% and 24.1% when
selecting the lowest tertile, quartile and quintile of patients
with depressed HRV, respectively (HRV index #21 U,
#19 U and #17.5 U, respectively). The analysis also
showed that, in the placebo arm, the mortality increase with
depressed HRV values was mainly caused by an increase in
the cardiac arrhythmic mortality. The nonarrhythmic mor-
tality was also increased, but to a lesser extent.
The test of prospective risk stratification based on HRV
values was successful. The criterion HRV index #20 U
selected approximately 30% of the total population of the
substudy with a 70% increase of the placebo arm all-cause
mortality and a 90% increase of placebo arm arrhythmic
mortality (compared with all-cause and arrhythmic mortal-
ity in the total placebo arm). Although the mortality
reduction on amiodarone in the prospectively stratified
population did not reach the level of statistical significance,
the hypothesis that these patients with depressed HRV
Figure 3. Dependence of mortality during EMIAT follow-up on the cut-off values of depressed HRV. For each HRV value, the graphs
show the mortality in patients with HRV measure # the value on the horizontal axis (that is, when using the value on the horizontal axis
as a dichotomy cut-off). Open areas 5 noncardiac mortality; grey areas 5 cardiac nonarrhythmic mortality; solid areas 5 arrhythmic
mortality. HRV 5 heart rate variability.
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benefit from prophylactic antiarrhythmic treatment (e.g.,
with amiodarone) should not be denied because EMIAT
was not powered for testing this hypothesis, and the
reduction of all-cause mortality from 22.8% on placebo to
17.5% on amiodarone is impressive. On the contrary, we
observed a mild increase of mortality on amiodarone
(12.8%) compared with placebo (9.5%) in patients with
prospectively defined preserved HRV.
Figure 4. Top graphs 5 mortality reduction on amiodarone in patients with depressed HRV. For each patient category and for each
dichotomy of HRV, the graphs show the mortality reduction on amiodarone during the follow-up of EMIAT, that is, the value ([mortality
on placebo] 2 [mortality on amiodarone])/[mortality on placebo], in patients with HRV # the given dichotomy. Bottom graphs 5
statistical significance of the difference between survival on placebo and survival on amiodarone in groups of patients selected in the same
way (the vertical axes show the l/p values—the higher the more significant; the statistical significance p 5 0.05 corresponds to the value
of 20 on the vertical axes). Note that the ranges of horizontal axes of graphs for both HRV index and standard deviation of normal to
normal intervals correspond approximately to the range of 10% to 40% of the population of the study. arrhythmia 5 arrhythmia signs on
Holter (see the text for details); BB 5 beta-blockers; fast HR 5 baseline short-term heart rate $ 75 beats/min; HRV 5 heart rate
variability; low LVEF 5 left ventricular ejection fraction # 30%; MI 5 myocardial infarction. Solid line 5 all patients; open square 5
first MI; solid square 5 on beta-blockers; open triangle 5 low LVEF; open diamond 5 arrhythmia; Ex 5 fast heart rate.
Table 8. Mortality in Retrospectively Selected Patients With Reduced and Preserved Heart Rate Variability (HRV Index # 19 U
and . 19 U)
HRV Index < 19 U HRV Index > 19 U
All-cause Mortality Arrhythmic Mortality All-cause Mortality
PA AA p Value PA AA p Value PA AA p Value
All patients 23.9% 17.1% 0.15 14.2% 3.8% 0.0017 9.9% 13.1% 0.14
Patients with first MI 18.4% 9.3% 0.046 11.4% 1.7% 0.0029 8.0% 8.1% 0.99
Patients on beta-blockers 16.4% 5.1% 0.047 9.0% 1.7% 0.074 8.4% 8.5% 0.99
Patients with LVEF #30% 29.8% 20.4% 0.16 18.1% 5.1% 0.0066 13.2% 17.9% 0.19
Patients with arrhythmia 33.3% 22.2% 0.19 17.5% 3.2% 0.010 15.4% 20.1% 0.26
Patients with HR $75 beats/min 30.0% 18.6% 0.054 17.3% 4.2% 0.0017 12.8% 17.0% 0.31
The p values refer to the log-rank test of Kaplan-Meier survival models (to be compared with the p values in Table 2).
AA 5 amiodarone arm; HR 5 baseline heart rate; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PA 5 placebo arm.
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The retrospective analysis suggested that an even higher
reduction of all-cause mortality with antiarrhythmic treat-
ment might be expected in patients at greater arrhythmia
risk, e.g., when selecting 20%–25% patients with lowest
HRV values. This is especially the case when depressed
HRV is combined with other arrhythmia risk factors, such
as arrhythmia signs on Holter (12–14) or increased heart
rate (15,16).
Finally, from the technical point of view of HRV assess-
ment, the study indicates that, in long-term Holter record-
ings of a large multicenter trial, the quality of data required
to obtain the correct values of statistical measures of HRV
is difficult to achieve. In such a setting, more robust
methods for HRV assessment (such as the geometrical
HRV index method) are probably more appropriate because
they are not so highly dependent on precise localization and
morphological classification of every single QRS complex.
The usual misrecognitions of computerized Holter analysis
are not only linked to improper handling of intervals
containing ectopic beats but, possibly more frequently, to
incorrect interpretations of myopotentials and tall T waves
as QRS complexes as well as to omission of low voltage
QRS complexes. This created both artificially short and
artificially long RR intervals, which distorted the statistical
measures of HRV despite filtering techniques that excluded
obvious jumps in the RR interval series; it is know that these
procedures of off-line post-process “data improvement” are
frequently of little help (8).
Relation to previous reports. In many previous reports,
depressed HRV was reported to be associated with adverse
outcome in survivors of acute MI (3–5,17–19). This is
confirmed by our observation, which shows that depressed
HRV remains a risk predictor in a population prestratified
according to other recognized risk factors (e.g., placebo
all-cause mortality 22.8% vs. 9.5% in patients with prospec-
tively defined reduced and preserved HRV—HRV index
dichotomized at 20 U).
The prospective hypothesis of this study was based on
previous observations showing that, compared with low
LVEF, depressed HRV predicts arrhythmic postinfarction
complications more strongly than nonarrhythmic events (6)
and that patients can be selected who are at predominantly
arrhythmic risk (20). The results of our retrospective sub-
study are in concordance with reports showing that dichot-
omy limits optimized in a univariate setting might need to
Figure 5. Survival curves in patients selected by a retrospectively defined criterion heart rate variability index # 19 U. In each case, the
p value corresponds to the log-rank statistics of the Kaplan-Meier survival model. Bold line 5 placebo arm; fine line 5 amiodarone arm.
arrhythmia 5 arrhythmia signs on Holter (see the text for details); fast heart rate 5 baseline short-term heart rate $ 75 beats/min; low
LVEF 5 left ventricular ejection fraction # 30%; MI 5 myocardial infarction.
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be changed when the combination of more risk factors is
considered (21). As the population of EMIAT was pre-
stratified in respect to low LVEF, it is not surprising that
the prospectively set dichotomy limit of HRV index #20 U
that was taken from studies of a total postinfarction popu-
lation (5) is not quite optimum and that other cut-off limits
led to a more striking difference between placebo and
amiodarone mortality.
The fact that depressed HRV becomes a more potent risk
predictor when combined with other risk factors has been
already observed (2,22,23). In particular, the combination of
depressed HRV with increased heart rate has been reported
to increase the predictive power of both factors (16), and
similar findings have been noted for combinations of HRV
with arrhythmia signs (20).
Beta-blockers and amiodarone have been reported to
have synergistic or additive pharmacological effects with
respect to their ability to suppress arrhythmias (24,25). The
combination of the two drugs might be dangerous in
patients with low heart rates or atrioventricular conduction
disturbances (26). The combined effect of amiodarone and
beta-blockers in EMIAT has been discussed in more detail
elsewhere (9). In brief, the finding that amiodarone is
particularly effective in patients on beta-blockers must be
interpreted with caution because a positive interaction
between amiodarone and beta-blockers was not envisaged
prospectively. As the patients of EMIAT were not random-
ized with respect to treatment with beta-blockers, it is
possible that patients prescribed beta-blockers on clinical
grounds are those with lower risk of nonarrhythmic mor-
tality in whom the antiarrhythmic action of amiodarone
might be particularly effective. Also, in addition to an
adrenergic inhibitory action, amiodarone has direct effects
on the action potential of sinus nodal cells and, indepen-
dently of beta-blocker treatment, it may have a positive
effect due to the reduction of heart rate (27,28). At the same
time, it is interesting to note that the potential benefit of the
combination of amiodarone with beta-blockers is practically
restricted to patients with reduced HRV.
Similar caution is needed in interpreting the observation
that amiodarone is particularly effective in patients with first
MI and that HRV is particularly potent in selecting those of
these patients who benefit from amiodarone treatment. The
differences in response to amiodarone between patients
without and with a history of previous MI have not been
seen in other studies of the drug, and the predictive power
of HRV has not been previously observed to differ in
patients with first and subsequent MI.
Study limitations. European Myocardial Infarct Amioda-
rone Trial was not designed and powered to test the
prospective hypothesis of this substudy, and the prospective
analysis did not reach statistical significance. In the light of
this, our finding is clearly insufficient to change the clinical
practice of prophylactic management of survivors of acute
MI. The HRV data of other amiodarone trials in infarction
survivors, where available, need to be urgently analyzed in a
prospective fashion, preferably using the dichotomies of
HRV index #20 U and #19 U. If the observations made
here are reproduced, clinical practice may indeed need to be
changed.
Retrospective subgroup analysis, even when based on
baseline parameters and when supported by previously made
observations, is, at best, hypothesis generating. Our retro-
spective analysis might, therefore, serve merely as a basis for
future prospective trials where amiodarone or any other
antiarrhythmic agent could be tested in patients with a
recent MI. Those results of the retrospective analysis that
are not supported by previous independent observations
require further detailed analysis. This is particularly the case
with the predictive power of depressed HRV in patients
with first MI.
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